AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells
Open Access
- 4 November 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-11
Abstract
Background: Androgens, through their own receptor, play a protective role on breast tumor development and progression and counterbalance estrogen-dependent growth stimuli which are intimately linked to breast carcinogenesis.Methods: Cell counting by trypan blu exclusion was used to study androgen effect on estrogen-dependent breast tumor growth. Quantitative Real Time RT–PCR, western blotting, transient transfection, protein immunoprecipitation and chromatin immunoprecipitation assays were carried out to investigate how androgen treatment and/or androgen receptor overexpression influences the functional interaction between the steroid receptor coactivator AIB1 and the estrogen- or androgen receptor which, in turn affects the estrogen-induced cyclin D1 gene expression in MCF-7 breast cancer cells. Data were analyzed by ANOVA.Results: Here we demonstrated, in estrogen receptor α (ERα)-positive breast cancer cells, an androgen-dependent mechanism through which ligand-activated androgen receptor (AR) decreases estradiol-induced cyclin D1 protein, mRNA and gene promoter activity. These effects involve the competition between AR and ERα for the interaction with the steroid receptor coactivator AIB1, a limiting factor in the functional coupling of the ERα with the cyclin D1 promoter. Indeed, AIB1 overexpression is able to reverse the down-regulatory effects exerted by AR on ERα-mediated induction of cyclin D1 promoter activity. Co-immunoprecipitation studies indicated that the preferential interaction of AIB1 with ERα or AR depends on the intracellular expression levels of the two steroid receptors. In addition, ChIP analysis evidenced that androgen administration decreased E2-induced recruitment of AIB1 on the AP-1 site containing region of the cyclin D1 gene promoter.Conclusions: Taken together all these data support the hypothesis that AIB1 sequestration by AR may be an effective mechanism to explain the reduction of estrogen-induced cyclin D1 gene activity. In estrogen-dependent breast cancer cell proliferation, these findings reinforce the possibility that targeting AR signalling may potentiate the effectiveness of anti-estrogen adjuvant therapies.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG15738, IG11595)
- Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR ex 60%)
This publication has 74 references indexed in Scilit:
- DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferationCell Death & Disease, 2013
- Analysis of Cyclin D1 in Breast Cancer: A Call to ArmsCurrent Breast Cancer Reports, 2012
- Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse modelsAnnals of the New York Academy of Sciences, 2011
- Dynamic modelling of oestrogen signalling and cell fate in breast cancer cellsNature Reviews Cancer, 2011
- Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal WomenClinical Cancer Research, 2011
- Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response elementNucleic Acids Research, 2010
- Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen ReceptorJournal of Biological Chemistry, 2010
- ChIP‐Seq of ERα and RNA polymerase II defines genes differentially responding to ligandsThe EMBO Journal, 2009
- Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1Cell, 2005
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997